PCSK9 Inhibitor Shown Highly Effective in High-Risk Patients Without Prior Heart Disease

New data from the VESALIUS-CV trial challenges conventional wisdom on aggressive cholesterol-lowering therapy.

Mar. 29, 2026 at 4:19pm

Got story updates? Submit your updates here. ›

New data presented at the American College of Cardiology 2026 Scientific Session suggests that adding the PCSK9 inhibitor evolocumab to statin therapy can significantly reduce the risk of major cardiovascular events in high-risk patients without prior heart attack or stroke. The findings indicate that more intensive LDL cholesterol targets, even below 40 mg/dL, may be appropriate for certain high-risk individuals, particularly those with diabetes.

Why it matters

These results could have significant implications for treatment guidelines, as the most aggressive LDL cholesterol targets have traditionally been reserved for patients who have already experienced a cardiovascular event. Expanding the use of PCSK9 inhibitors to a broader population of high-risk individuals without known atherosclerosis may lead to improved cardiovascular outcomes, but cost-effectiveness remains a barrier to widespread adoption.

The details

The VESALIUS-CV trial included over 12,000 high-risk patients, including 3,365 with diabetes but no evidence of atherosclerosis. Patients treated with evolocumab in addition to statins experienced a 59 mg/dL reduction in LDL cholesterol after 48 weeks, reaching a median level of 52 mg/dL. At 96 weeks, the median LDL in the evolocumab group was even lower, at 44 mg/dL. This aggressive LDL lowering resulted in a 2.1% absolute reduction in the risk of a three-point MACE (coronary heart disease death, MI, or ischemic stroke) over five years, as well as a 2.9% reduction in the risk of a four-point MACE that included ischemia-driven revascularization. Importantly, both all-cause and cardiovascular mortality were significantly lower in the evolocumab group.

  • The VESALIUS-CV trial data was presented at the American College of Cardiology 2026 Scientific Session.
  • The 2026 dyslipidemia guidelines were released after the VESALIUS-CV trial data became available.

The players

Dr. Nicholas Marston

A researcher from Brigham and Women's Hospital in Boston, MA, who led the analysis of the VESALIUS-CV trial data.

Dr. Ann Marie Navar

A cardiologist from UT Southwestern Medical Center in Dallas, TX, who highlighted the growing awareness that 'lower is better' when it comes to LDL cholesterol, even in primary prevention.

John D. Bucheit

A pharmacist from Virginia Commonwealth University in Richmond, who emphasized the need to re-examine LDL targets for high-risk primary prevention patients and expressed hope that the VESALIUS-CV findings will lead to improved insurance coverage for PCSK9 inhibitors.

Amgen

The pharmaceutical company that manufactures the PCSK9 inhibitor evolocumab (Repatha).

Got photos? Submit your photos here. ›

What they’re saying

“We are currently using evolocumab for patients with high-risk atherosclerosis, so this subgroup with no known atherosclerosis is really a novel group.”

— Dr. Nicholas Marston, Researcher, Brigham and Women's Hospital

“It's not going to acquire you to the goal, to the guideline-directed target of less than 70 mg/dL, on average, in that group. Sometimes we just need a larger benefit or larger reduction with your drug.”

— Dr. Nicholas Marston, Researcher, Brigham and Women's Hospital

“Lower is better' when it comes to LDL cholesterol, even in primary prevention.”

— Dr. Ann Marie Navar, Cardiologist, UT Southwestern Medical Center

What’s next

The key takeaway is that a more proactive approach to cardiovascular risk reduction may be warranted for a broader range of patients than previously thought. As Dr. Marston noted, PCSK9 inhibitors have been available for over a decade, but their uptake in clinical practice has been unhurried. He hopes this new analysis will encourage wider use of these powerful medications, particularly in primary care and other specialties.

The takeaway

The findings from the VESALIUS-CV trial suggest that more aggressive LDL cholesterol targets, even below 40 mg/dL, may be appropriate for certain high-risk individuals, particularly those with diabetes. This shift in thinking could have significant implications for treatment guidelines and lead to improved cardiovascular outcomes, though cost-effectiveness remains a barrier to widespread adoption of PCSK9 inhibitors.